https://doi.org/10.4081/ejtm.2024.13108
Obsessive-compulsive disorder, major depressive disorder, and addiction: the vicious relationship
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 13 November 2024
Obsessive-Compulsive Disorder (OCD) and Major Depressive Disorder (MDD) are prevalent psychiatric conditions, each affecting a substantial portion of the global population. When these conditions coexist with a Substance Use Disorder (SUD), the complexity of the clinical presentation is heightened. Herein, we describe two cases of individuals who have comorbid OCD and/or MDD and substance use disorder that highlight the importance of addressing the coexisting psychiatric illness when treating the SUD. These cases highlight the importance of tailored, multidisciplinary care, offering a potential therapeutic strategy based on medications for comprehensive recovery in individuals facing complex comorbid disorders. An integrated treatment approach, encompassing both psychiatric and substance treatment perspectives, is imperative.
Downloads
Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593–602. DOI: https://doi.org/10.1001/archpsyc.62.6.593
Leshner AI. Addiction is a brain disease, and it matters. Science 1997;278:45-7. DOI: https://doi.org/10.1126/science.278.5335.45
McLellan AT. Substance misuse and substance use disorders: Why do they matter in healthcare? Trans Am Clin Climatol Assoc 2017;128:112-30.
U.S. Department of Justice, National Drug Intelligence Center. National Drug Threat Assessment 2011. Published August 2011. Accessed 31 October 2023. Available from: https://www.justice.gov/archive/ndic/pubs44/44849/44849p.pdf
Mattson CL, Tanz LJ, Quinn K, et al. Trends and georgraphic patterns in drug and synthetic opioid overdose deaths – United States, 2013 – 2019. MMWR Morb Mortal Wkly Rep 2021;70:202-7. DOI: https://doi.org/10.15585/mmwr.mm7006a4
Ross S, Peselow E. Co-occurring psychotic and addictive disorders: Neurobiology and diagnosis. Clin Neuropharmacol 2012;35:235-43. DOI: https://doi.org/10.1097/WNF.0b013e318261e193
Veale D, Roberts A. Obsessive-compulsive disorder. BMJ 2014;348:g2183. DOI: https://doi.org/10.1136/bmj.g2183
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). American Psychiatric Press, Washington, DC. 2013. DOI: https://doi.org/10.1176/appi.books.9780890425596
Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2006;67:247-57. DOI: https://doi.org/10.4088/JCP.v67n0211
Virtanen S, Kuja-Halkola R, Sidorchuk A, et al. Association of obsessive-compulsive disorder and obsessive-compulsive symptoms with substance misuse in 2 longitudinal cohorts in Sweden. JAMA Netw Open 2022;5:e2214779. DOI: https://doi.org/10.1001/jamanetworkopen.2022.14779
Mancebo MC, Grant JE, Pinto A, Eisen JL, Rasmussen SA. Substance use disorders in an obsessive compulsive disorder clinical sample. J Anxiety Disord 2009;23:429-35. DOI: https://doi.org/10.1016/j.janxdis.2008.08.008
Quarantini LC, Torres AR, Sampaio AS, et al. Comorbid major depression in obsessive-compulsive disorder patients. Compr Psychiatry 2011;52:386-93. DOI: https://doi.org/10.1016/j.comppsych.2010.09.006
Hunt GE, Malhi GS, Lai HMX, Cleary M. Prevalence of comorbid substance use in major depressive disorder in community and clinical settings, 1990-2019: Systematic review and meta-analysis. J Affect Disord 2020;266:288-304. DOI: https://doi.org/10.1016/j.jad.2020.01.141
Brenner P, Brandt L, Li G, et al. Treatment-resistant depression as risk factor for substance use disorders-a nation-wide register-based cohort study. Addiction 2019;114:1274-82. DOI: https://doi.org/10.1111/add.14596
Badiani A, Belin D, Epstein D, et al. Opiate versus psychostimulant addiction: the differences do matter. Nat Rev Neurosci 2011;12:685-700. DOI: https://doi.org/10.1038/nrn3104
Grassi G. Addicted to compulsion: Assessing three core dimensions of addiction across obsessive-compulsive disorder and gambling disorder. CNS Spectrums. 2020. doi:10.1017/S1092852919000993 DOI: https://doi.org/10.1017/S1092852919000993
Kelly TM, Daley DC, Douaihy AB. Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav 2012;37:11-24. DOI: https://doi.org/10.1016/j.addbeh.2011.09.010
Torrens M, Rossi PC, Martinez-Riera R, et al. Psychiatric co-morbidity and substance use disorders: treatment in parallel systems or in one integrated system? Subst Use Misuse 2012;47:1005-14. DOI: https://doi.org/10.3109/10826084.2012.663296
Kelly TM, Daley DC. Integrated treatment of substance use and psychiatric disorders. Soc Work Public Health 2013;28:388-406. DOI: https://doi.org/10.1080/19371918.2013.774673
Agabio R, Trogu E, Pani PP. Antidepressants for the treatment of people with co-occurring depression and alcohol dependence. Cochrane Database Syst Rev 2018;4:CD008581. DOI: https://doi.org/10.1002/14651858.CD008581.pub2
Hassan AN, Howe AS, Samokhvalov AV, et al. Management of mood and anxiety disorders in patients receiving opioid agonist therapy: Review and meta-analysis. Am J Addict 2017;26:551-63. DOI: https://doi.org/10.1111/ajad.12581
Xu J, Hao Q, Qian R, et al. Optimal dose of serotonin reuptake inhibitors for obsessive-compulsive disorder in adults: A systematic review and dose-response meta-analysis. Front Psychiatry 2021;12:717999. DOI: https://doi.org/10.3389/fpsyt.2021.717999
SAMHSA, Substance Abuse and Mental Health Services Administration. Obsessive-compulsive disorder and substance use disorders. Advisory 2016;15:1-9.
Torres AR, Ramos-Cerqueira AT, Ferrão YA, et al. Suicidality in obsessive-compulsive disorder: Prevalence and relation to symptom dimensions and comorbid conditions. J Clin Psychiatry 2011;72:17-26; Quiz 119-20. DOI: https://doi.org/10.4088/JCP.09m05651blu
Satel SL, McDougle CJ. Obsessions and compulsions associated with cocaine abuse. Am J Psychiatry 1991;148:947. DOI: https://doi.org/10.1176/ajp.148.7.947a
Koran LM, Aboujaoude E, Bullock KD, et al. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2005;66:353-9. DOI: https://doi.org/10.4088/JCP.v66n0312
Sun J, Li Z, Buys N, Storch EA. Correlates of comorbid depression, anxiety and helplessness with obsessive-compulsive disorder in Chinese adolescents. J Affect Disord 2015;174:31-7. DOI: https://doi.org/10.1016/j.jad.2014.11.004
Tibi L, van Oppen P, van Balkom AJLM, et al. The long-term association of OCD and depression and its moderators: A four-year follow up study in a large clinical sample. Eur Psychiatry 2017;44:76-82. DOI: https://doi.org/10.1016/j.eurpsy.2017.03.009
Remijnse PL, van den Heuvel OA, Nielen MM, et al. Cognitive inflexibility in obsessive-compulsive disorder and major depression is associated with distinct neural correlates. PLoS One 2013;8:e59600. DOI: https://doi.org/10.1371/journal.pone.0059600
Rickelt J, Viechtbauer W, Lieverse R, et al. The relation between depressive and obsessive-compulsive symptoms in obsessive-compulsive disorder: Results from a large, naturalistic follow-up study. J Affect Disord 2016;203:241-7. DOI: https://doi.org/10.1016/j.jad.2016.06.009
Moritz S, Rufer M, Fricke S, et al. Quality of life in obsessive-compulsive disorder before and after treatment. Compr Psychiatry 2005;46:453-9. DOI: https://doi.org/10.1016/j.comppsych.2005.04.002
Dhillon S, Yang LP, Curran MP. Spotlight on bupropion in major depressive disorder. CNS Drugs 2008;22:613-7. DOI: https://doi.org/10.2165/00023210-200822070-00006
Vulink NCC, Denys D, Westenberg HGM. Bupropion for patients with obsessive-compulsive disorder: An open-label, fixed-dose study. J Clin Psychiatry 2005;66:228-30. DOI: https://doi.org/10.4088/JCP.v66n0211
Kellner M. Drug treatment of obsessive-compulsive disorder. Dialogues Clin Neurosci 2010;12:187-97. DOI: https://doi.org/10.31887/DCNS.2010.12.2/mkellner
Pittenger C, Bloch MH. Pharmacological treatment of obsessive-compulsive disorder. Psychiatr Clin North Am 2014;37:375-91. DOI: https://doi.org/10.1016/j.psc.2014.05.006
Bakhshaie J, Storch EA, Zvolensky MJ. Obsessive-compulsive symptoms and problematic alcohol use: The explanatory role of drinking motives. Addict Behav 2021;115:106734. DOI: https://doi.org/10.1016/j.addbeh.2020.106734
Öst LG, Enebrink P, Finnes A, et al. Cognitive behavior therapy for obsessive-compulsive disorder in routine clinical care: A systematic review and meta-analysis. Behav Res Ther 2022;159:104170. DOI: https://doi.org/10.1016/j.brat.2022.104170
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.